Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori

American Journal of Gastroenterology

Volumn 99, Issue 10, 2004, Pages 1910-1915

  Ricci, Chiara ^b   Vakil, Nimish ^b   Rugge, Massimo ^b   Gatta, Luigi ^b   Perna, Federico ^b   Osborn, John F ^b   Russo, Valentina M ^b   Tampieri, Andrea ^b   Bernabucci, Veronica ^b   Miglioli, Mario ^b   Vaira, Dino ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; PEPSINOGEN; PEPSINOGEN I; PEPSINOGEN II; UREASE;

ADULT; ANTRUM PREDOMINANT GASTRITIS; ARTICLE; ATROPHIC ANTRUM RESTRICTED GASTRITIS; ATROPHIC GASTRITIS; CHRONIC DISEASE; CONTROLLED STUDY; CORPUS RESTRICTED GASTRITIS; DISEASE MARKER; FEMALE; GASTRIN BLOOD LEVEL; GASTRITIS; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INFECTION; MAJOR CLINICAL STUDY; MALE; NONATROPHIC GASTRITIS; PRECANCER; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SERODIAGNOSIS; STOMACH BIOPSY; STOMACH CANCER; TISSUE CULTURE; VOLUNTEER;

ATROPHY; BIOLOGICAL MARKERS; FEMALE; GASTRINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPSINOGEN A; REPRODUCIBILITY OF RESULTS; SINGLE-BLIND METHOD; STOMACH;

EID: 7044226441     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2004.40614.x     Document Type: Article

References (25)

1. International Agency for Research on Cancer, World Health Organization. Infection with Helicobacter pylori. In: Schistosomes, liver flukes and Helicobacter pylori. Lyon: IARC, 1994:177-202.
2. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-9.
3. Mulholland G, Ardill JE, Fillmore D, et al. Helicobacter pylori related hypergastrinaemia is the result of a selective increase in gastrin 17. Gut 1993;34:757-61.
4. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992;102: 760-6.
5. Plebani M, Basso D, Cassaro M, et al. Helicobacter pylori serology in patients with chronic gastritis. Am J Gastroenterol 1996;91:954-8.
6. Vaira D, Vakil N, Rugge M, et al. Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut 2003;52:1543-7.
7. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of H pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167.
8. Rugge M, Cassaro M, Leandro G, et al. Atrophic gastritis: Pathology and endoscopy in the reversibility assessment. Gut 2003;52:1387-8.
9. Jass JR, Filipe MI. The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gastric carcinoma. J Histochem 1981;13:931-9.
10. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-81.
11. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: Interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002; 16(7):1249-59.
12. Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigens of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A 1993;90:5791-5.
13. Altman DG. Roc curve. In practical statistics for medical research. London: Chapman & Hall/CRC, 1991:417-78.
14. Altman DG. Diagnostic tests. Statistics with confidences. 2nd Ed. Edited by Altman DG, Machin D, Trevor NB, Gardner MJ. BMJ Books, 2000.
15. Debanne SM, Rowland DY. Logistic regression. Gastrointest Endosc 2002;55:142-3.
16. Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305-15.
17. Sung JJ, Lin SR, Ching JY, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: A prospective, randomized study. Gastroenterology 2000;119:7-14.
18. Ohkusa T, Fujiki K, Takashimizu I, et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001;134:380-6.
19. Correa P, Cuello C, Duque E. Carcinoma and intestinal metaplasia of the stomach in Colombian migrants. J Natl Cancer Inst 1970;44(2):297-306.
20. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003;139:463-9.
21. Sjölund M, Wreiber K, Andersson DI, et al. Long-term persistence of resistant enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 2003;139:483-7.
22. Broutet N, Plebani M, Sakarovitch C, et al. Pepsinogen A pepsinogen C, and gastrin as markers of atrophic chronic qastritis in European dyspeptics. Br J Cancer 2003;88:1239-47.
23. Sipponen P, Ranta P, Helske T, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: An observational case-control study. Scand J Gastroenterol 2002;377:85-91.
24. Miki K, Morita M, Sasajima M, et al. Use fulness of qastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003;98:735-9.
25. Knight T, Wyatt J, Wilson A, et al. Helicobacter pylori gastritis and serum pepsinogen levels in a healthy population: developement of a biomarker strategy for gastric atrophy in high risk groups. Br J Cancer 1996;73:819-24.